Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00621153 |
To compare the changes in mean sitting DBP from baseline after 4 weeks of therapy with either candesartan cilexetil/HCT combination therapy or candesartan cilexetil monotherapy regimen
Condition | Intervention | Phase |
---|---|---|
Stage II Hypertension |
Drug: Candesartan Cilexetil Drug: Hydrochlorothiazide |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Open-Label, Randomised, 2-Arm Parallel Group, Multicentre, 8-Week, Phase IV Study to Assess the Antihypertensive Efficacy and Safety of the Candesartan Cilexetil 16 mg and Hydrochlorothiazide 12.5 mg Combination Therapy in Comparison With Candesartan 16 mg Monotherapy in Hypertensive Adults |
Enrollment: | 214 |
Study Start Date: | February 2008 |
Study Completion Date: | March 2009 |
Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
Candesartan cilexetil 16mg monotherapy
|
Drug: Candesartan Cilexetil
Candesartan Cilexetil 16 mg oral
|
2: Experimental
Candesartan cilexetil 16mg/HCT combination therapy
|
Drug: Candesartan Cilexetil
Candesartan Cilexetil 16 mg oral
Drug: Hydrochlorothiazide
Hydrochlorothiazide 12.5 mg
|
3: Active Comparator
candesartan cilexetil 32mg monotherapy
|
Drug: Candesartan Cilexetil
Candesartan Cilexetil 32 mg oral
|
4: Experimental
Candesartan Cilexetil 32 mg/HCT combination therapy
|
Drug: Hydrochlorothiazide
Hydrochlorothiazide 12.5 mg
Drug: Candesartan Cilexetil
Candesartan Cilexetil 32 mg oral
|
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Korea, Republic of | |
Research Site | |
Seoul, Korea, Republic of |
Principal Investigator: | Dong Hoon Choi | Severance Hospital |
Study Director: | Joonwoo Bahn | AstraZeneca Korea |
Study ID Numbers: | D2452L00016 |
Study First Received: | January 24, 2008 |
Last Updated: | April 29, 2009 |
ClinicalTrials.gov Identifier: | NCT00621153 History of Changes |
Health Authority: | Korea: Food and Drug Administration |
Candesartan Cilexetil hydrochlorothiazide severe hypertension |
Angiotensin II Type 1 Receptor Blockers Candesartan cilexetil Sodium Chloride Symporter Inhibitors Diuretics Candesartan Vascular Diseases |
Cardiovascular Agents Angiotensin II Antihypertensive Agents Hydrochlorothiazide Hypertension |
Molecular Mechanisms of Pharmacological Action Diuretics Physiological Effects of Drugs Sodium Chloride Symporter Inhibitors Vascular Diseases Cardiovascular Agents Antihypertensive Agents Hydrochlorothiazide Pharmacologic Actions |
Angiotensin II Type 1 Receptor Blockers Candesartan cilexetil Membrane Transport Modulators Natriuretic Agents Therapeutic Uses Candesartan Cardiovascular Diseases Hypertension |